June 4, 2025 -
Pittsburgh, USA – June 4, 2025 – MolecuLight Corp., a global pioneer in point-of-care fluorescence imaging for rapid detection of infection causing bacteria in wounds, is pleased to announce its participation in the Society for Vascular Surgery (SVS) Vascular Annual Meeting (VAM), taking place in New Orleans,
… Read MoreApril 29, 2025 -
Toronto, Canada – April 29, 2025 – MolecuLight Corp., a global pioneer in point-of-care fluorescence imaging for rapid detection of infection causing bacteria in wounds, and DocNow, an innovative post-acute Electronic Health Record (EHR) platform, today announced their integration for the MolecuLightDX™ device.
This powerful collaboration will
… Read MoreApril 8, 2025 -
Toronto, Canada – April 8th, 2025 – MolecuLight, a global pioneer in point-of-care fluorescence imaging for rapid bacterial detection in wounds, announces its presence at the American Burn Association (ABA) Annual Meeting in Phoenix, AZ, April 8-11. MolecuLight will showcase its innovative fluorescence imaging systems that empower
… Read MoreApril 3, 2025 -
Toronto, Canada – April 3rd, 2025 – A groundbreaking study published in the Journal of Vascular Surgery: Venous and Lymphatic Disorders has unveiled a significant relationship between bacterial load and pain in patients with venous leg ulcers (VLUs), showcasing the potential of MolecuLight’s fluorescence imaging technology to
… Read MoreFebruary 28, 2025 -
Pittsburgh, PA – 2/28/2025 – MolecuLight Inc., the leader in point-of-care fluorescence imaging devices for wound care, is excited to announce its participation in the 2025 Cellular, Acellular, and Matrix-like Products (CAMPs) Wound Care Summit, held from February 28th to March 2nd in Fort Lauderdale, Florida. In
… Read MoreJanuary 28, 2025 -
Toronto, CANADA – January 28th, 2025 – MolecuLight Corp., a leader in point-of-care fluorescence imaging for wound care, is excited to announce that Dr. Michael N. Desvigne, a renowned board-certified plastic surgeon and wound care clinician, will present the clinical and surgical benefits of MolecuLight’s fluorescence imaging
… Read MoreJanuary 9, 2025 -Strategic financing will enable MolecuLight to further accelerate commercialization
Pittsburgh, PA January 6, 2025 – MolecuLight Inc.., a global medical device company pioneering point-of-care fluorescence imaging for measuring bacterial load in wounds, today announced it has secured a $27.5 million investment from Hayfin Capital Management LLP (“Hayfin”).
… Read MoreMay 30, 2024 -
Toronto, CANADA – May 30th, 2024 – MolecuLight Inc., the global leader in fluorescence imaging technology for real-time detection of harmful bacteria in wound care, celebrates the publication of a groundbreaking study in the prestigious Burns Journal. Titled “Bacterial Fluorescence Imaging as a Predictor
… Read MoreMay 2, 2024 -Wide-Spread Clinical Evidence using the MolecuLight Imaging Platform Reveals its Significant Global Adoption and Proven Utility in Wound Care
Toronto, CANADA and London, UK – (May 1, 2024) – MolecuLight Corp., the leader in point-of-care digital wound measurement and real-time bacterial detection through fluorescence imaging, announces that its MolecuLight wound imaging
… Read More
MolecuLight is SOC ll®
Type l Accredited:
MolecuLight awarded
Premier’s Technology
Breakthrough Designation
MolecuLight i:X
is designated as a:
MolecuLight included
in ISWCAP Consensus
Guidelines:
MolecuLight is a proud
corporate member of:
©2025
The MolecuLight® i:X and MolecuLightDX™ Imaging Devices are approved by Health Canada for sale in Canada and has CE marking for sale in the European Union.
The MolecuLight™ i:X and DX Imaging Devices have received FDA clearance.